The Food & Drug Administration’s accelerated approval pathway has been essential for speeding up the availability of new and effective treatments for patients with serious and often-life-threatening diseases where there are no other treatments available. Right now, efforts are underway that would undermine the pathway and risk bringing us back to a time when promising therapies languished in regulatory limbo while patients waited without any treatment options.
Patients’ voices are often absent from debates about the accelerated approval pathway, so we are sharing their stories here.
Learn how patients’ lives have been changed by treatments approved through the FDA’s accelerated approval pathway.
Ivy Elkins, Evanston, IL, Lung Cancer - https://bit.ly/3BEpOZd
Billy Ellsworth, Pittsburgh, PA, Duchenne Muscular Dystrophy - https://bit.ly/3gQSLca
Laura Kelly, Atlanta, GA, Nontuberculous Mycobacteria (NTM) - https://bit.ly/3yL2W8h
Jordan McLinn, Indianapolis, IN, Duchenne Muscular Dystrophy - https://bit.ly/3zA0pic
Teonna Woolford, Owings Mills, MD, Sickle Cell Disease - https://bit.ly/3mQXxdj
Marc Yale, Ventura, CA, Mucous Membrane Pemphigoid - https://bit.ly/38tyqon
As we work with partners, like the EveryLife Foundation for Rare Diseases, to build greater understanding around these critical programs and to hold public and private payers accountable to their mission of providing health care access to America’s most vulnerable populations, PFCD encourages you to learn more by visiting www.fightchronicdisease.org/resources/acceleratedapproval which includes backgrounders, economic analyses, American Journal of Managed Care commentary, infographics, opinion editorials and more.
To contribute a patient or provider story to this effort, please contact Jennifer.Burke@fightchronicdisease.org.